Ligand · IOR
IOR · N~5~-[(5R)-5-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-L-ornithine
IOR, N~5~-[(5R)-5-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl]-L-ornithine (C9 H16 N4 O3, 228.2 g/mol), in the MolNFT structures on GenesisL1: bound in 2 records (1 PDB entry). Every binding site with its residues within 4.5 Å, the residues…
- Component
- IOR
- Formula
- C9 H16 N4 O3
- Class
- ligand
- Structures
- 2
- PDB entries
- 1
Binding sites
IOR in 2 structures; the first of them:
- 2MOV · Receptor for Advanced Glycation End Products (RAGE) Specifically Recognizes Methylglyoxal… · IOR A201 · binds LYS32, ARG78, CYS79, GLN80, THR89, LYS90, SER91, ASN92
- 2MOV · Receptor for advanced glycation end products (rage) specifically recognizes methylglyoxal… · IOR A201 · binds LYS32, ARG78, CYS79, GLN80, THR89, LYS90, SER91, ASN92
Residues it binds most
LYS 2, ARG 2, ASN 2, CYS 2, GLN 2, SER 2, THR 2 (residue and the binding sites it lines).
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.